Reviewing Bioblast Pharma Ltd. (ORPN)’s and Geron Corporation (NASDAQ:GERN)’s results

We will be comparing the differences between Bioblast Pharma Ltd. (NASDAQ:ORPN) and Geron Corporation (NASDAQ:GERN) as far as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bioblast Pharma Ltd. N/A 0.00 3.33M -1.00 0.00
Geron Corporation 1.07M 292.00 27.02M -0.16 0.00

Table 1 demonstrates Bioblast Pharma Ltd. and Geron Corporation’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows Bioblast Pharma Ltd. and Geron Corporation’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Bioblast Pharma Ltd. 0.00% -101.1% -88.2%
Geron Corporation -2,525.23% -19.2% -18.5%

Risk and Volatility

A 1.46 beta means Bioblast Pharma Ltd.’s volatility is 46.00% more than Standard and Poor’s 500’s volatility. Geron Corporation on the other hand, has 2.96 beta which makes it 196.00% more volatile compared to Standard and Poor’s 500.

Liquidity

11.8 and 11.8 are the respective Current Ratio and a Quick Ratio of Bioblast Pharma Ltd. Its rival Geron Corporation’s Current and Quick Ratios are 37.8 and 37.8 respectively. Geron Corporation has a better chance of clearing its pay short and long-term debts than Bioblast Pharma Ltd.

Analyst Recommendations

Bioblast Pharma Ltd. and Geron Corporation Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Bioblast Pharma Ltd. 0 0 0 0.00
Geron Corporation 0 0 2 3.00

Competitively Geron Corporation has an average target price of $4, with potential upside of 139.52%.

Insider & Institutional Ownership

Roughly 19.5% of Bioblast Pharma Ltd. shares are owned by institutional investors while 34.1% of Geron Corporation are owned by institutional investors. Insiders owned roughly 36.85% of Bioblast Pharma Ltd.’s shares. Competitively, Geron Corporation has 0.48% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Bioblast Pharma Ltd. -6.62% 15.98% -2.31% 0.79% -50.58% 64.13%
Geron Corporation -0.66% 31.3% -2.58% -72.29% -37.34% 51%

For the past year Bioblast Pharma Ltd. was more bullish than Geron Corporation.

Summary

On 7 of the 10 factors Geron Corporation beats Bioblast Pharma Ltd.

Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.